TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01048398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: intervention: intravenous paracetamol 1g and remifentanil 1mg/100ml in 100ml of 0.9% saline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: Control group: intravenous paracetamol 1g
Study: NCT03980782

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Individualized music therapy developed playlist(s) that will be used based upon the latest Confusion Assessment Method result (hypoactive, hyperactive or no delirium) delivered twice daily.
Study: NCT02194946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM therapies
Description: The choice of CM patterns will be at the treating physician's discretion. The dosing regimen of Chinese herbs and Chinese patent medicine will be as per the 2010 Chinese pharmacopoeia.The oral Chinese herbal formula will be composed of 18 herbs:Radix Astragali, Radix Codonopsis, Rhizoma Atractylodis Macrocephalae, Rhizoma diosscoreae, Poria, Semen Cuscutae, Radix Morindae Officinalis, Herba Epimedii, Herba Cistanches, Fructus Ligustri Lucidi, Rhizoma Polygonati, Fructus Amomi, Herba Agastaches, Rhizoma Coptidis, Radix et Rhizoma Rhei, Semen Coicis, Radix Salviae Miltiorrhizae, and stir-baked Semen Persicae. The Chinese herbal formula via Colonic administration will be composed of 3 herbs: Radix et Rhizoma Rhei, Calcined Concha Osterae, Herba Taraxaci.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-related management
Description: Western medicine treatment for CKD are practised following KDIGO and KDOQI guidelines, to reach the recommended goals of nutrition, blood pressure, hemoglobulin, electrolytes, fluid control and acid-base balance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-related management
Description: Western medicine treatment for CKD are practised following KDIGO and KDOQI guidelines, to reach the recommended goals of nutrition, blood pressure, hemoglobulin, electrolytes, fluid control and acid-base balance.
Study: NCT01021176

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo spray
Description: 0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray yet no drug will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Description: 0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray Three Dilutions would be 5.5, 6.0 and 6.3 and the fourth at the filp of a coin randomly diluted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Description: 0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray Three Dilutions would be 5.5, 6.0 and 6.3 and the fourth at the filp of a coin randomly diluted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Description: 0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray Three Dilutions would be 5.5, 6.0 and 6.3 and the fourth at the filp of a coin randomly diluted.
Study: NCT00763256

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan, Fluoride
Description: subjects brushed their teeth twice daily with the study toothpaste for the assigned treatment period.
Study: NCT01372644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM 230 / Pasireotide
Study: NCT00763256

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: subjects brushed their teeth twice daily with the study toothpaste for the assigned study treatment period.
Study: NCT01899131

Intervention type: DEVICE
Group type: OTHER
Intervention: platform-switch tapered internal implants
Description: Laser-Lok permanent abutment/ new Laser Lok platform-switch implant assembly.assessment at 6,12,24 month clinicaly and radiographic
Study: NCT01877681

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tele-assistance
Description: Assisted care (Tele-assistance) provided by an expert nurse through a informatic online application

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: Usual care as specified in the PU practice guideline
Study: NCT01738685

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral Intervention.
Study: NCT00753961

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fermented dairy product
Description: fermented dairy product (2 bottles/day during 16 weeks)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non fermented dairy product
Description: non fermented dairy product (2 bottles/day during 16 weeks)
Study: NCT01679522

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-port laparoscopic surgical staging
Description: single-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Four-port laparoscopic surgical staging
Description: Four-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
Study: NCT02872324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procurement questionnaires
Study: NCT04322240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid
Description: Participants will be prescribed 600 mg/day ALA (thiotacid) orally, for 3 months, and will be advised not to discontinue this medication
Study: NCT04508062

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pectopexy operation
Description: Vaginal cuff or uterine cervix will be attached to iliopectineal ligament with polypropylene mesh on both sides.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pectopexy operation
Description: Vaginal cuff or uterine cervix will be attached to iliopectineal ligament with polypropylene mesh on both sides.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uterosacral ligaments plication operation.
Description: At least 2/3 of the sacrouterine ligaments will be shortened with helical sutures, starting from the cervix and so douglas will be partially obliterated.
Study: NCT01975675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF 90/400 mg FDC tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF 90/400 mg FDC tablet administered orally once daily
Study: NCT04178070

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, 10mg
Description: 10mg (500μL), single dose, abdominal subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, 15mg
Description: 15mg (750μL), single dose, abdominal subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, 20mg
Description: 20mg (1mL), single dose, abdominal subcutaneous injection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, 30mg
Description: 30mg (1.5mL), single dose, abdominal subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, 30mg
Description: 30mg (1.5mL), single dose, abdominal subcutaneous injection
Study: NCT01259115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole tablet
Description: Ketoconazole 200 mg tablets taken orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole tablet
Description: Ketoconazole 200 mg tablets taken orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match ketoconazole tablet
Description: Placebo to match ketoconazole 200 mg tablets taken orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to match ketoconazole tablet
Description: Placebo to match ketoconazole 200 mg tablets taken orally twice daily.
Study: NCT02045992

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffeine
Description: Five doses of 100mg of caffeine diluted in 100 ml of decaffeinated coffee. One dose every hour for five hours
Study: NCT02245022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50mg od
Description: Patients randomised to receive either Dolutegravir 50mg od or standard of care (Efavirenz 600mg od) plus Lamivudine 300mg od/ Tenofovir 300mg od

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Patients are randomised 1:1 to receive either Dolutegravir 50mg once daily in combination with Lamivudine 300mg od and tenofovir 300mg od or standard of care (Efavirenz 600mg plus Lamivudine 300mg od and tenofovir 300mg od)
Study: NCT03492827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorhexidine acetate gargle
Description: observe whether it can achieve the effect of preventing postoperative infection
Study: NCT01196676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4451
Description: 1 mg capsules, 5 mg capsules, and 25 mg capsules
Study: NCT01975675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, \> 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
Study: NCT03530618

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible tip straight guidewire
Description: Use a flexible tip straight guidewire for ultrasound-guided central venous catheterization

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J-tip
Description: Use a J tip straight guidewire for ultrasound-guided central venous catheterization
Study: NCT02859987

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PICC Placement by Landmark Technique
Description: Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PICC Placement by Ultrasound-guided Technique
Description: Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Scan
Description: Initially the nurses use ultrasound for explore venous anatomy and then they use real-time ultrasound imaging during needle placement
Study: NCT04020276

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Participants will receive 5 fractions of radiation, which will be delivered 2-3 times per week. SBRT should be complete in a 1.5 to 2 week time frame. There should be a minimum of 12 hours between treatments. Each fraction will be escalated or de-escalated to meet the overall constraints in phase IA or both previously identified constraints in phase IB
Study: NCT02915068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EHR-Physician Asthma Care Education Program
Description: participants will receive EHR-PACE, an interactive 1.5 hour training module that teaches clinicians best practices for communicating with patients in the presence of computer systems in the exam room (specifically EHRs).
Study: NCT01141218

Intervention type: OTHER
Intervention: internet-based protocol and physician referral
Description: collection and review, dna and lab biomarker analysis, gene mapping
Study: NCT01619592

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: webbased education (telemonitoring)
Description: Patients will be able to transmit their blood glucose values via the Internet to the diabetes professional and they will receive timely feedback. Timely will be defined as 'as agreed between the patient and the diabetes professional', e.g. every week on Friday afternoon.
Study: NCT01196676

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 mg capsules, 5 mg capsules, and 25 mg capsules
Study: NCT02518919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Child life intervention
Description: The participants will receive IV ketamine for sedation. In addition in this arm, 'Child Life Intervention', comfort measures provided by a trained child life therapist during painful procedures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music listening
Description: The participants will receive IV ketamine for sedation. In addition in this arm, 'Music Listening' to music chosen by the patient using headphones
Study: NCT03023176

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone® standard IIV3
Description: Influenza Virus Vaccine Suspension (0.5ml) for Intramuscular Injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fluzone® standard IIV3 Pediatric Dose
Description: Influenza Virus Vaccine Suspension (0.25ml) for Intramuscular Injection
Study: NCT04094376

Intervention type: OTHER
Group type: OTHER
Intervention: receiving operation during the day or at night
Description: eighty-four patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00) and the Night Group (18:00-22:00)

Intervention type: OTHER
Group type: OTHER
Intervention: receiving operation during the day or at night
Description: eighty-four patients scheduled for elective laparoscopic abdominal surgeries under general anesthesia were randomly assigned to receive operation in the Day Group (8:00-12:00) and the Night Group (18:00-22:00)
Study: NCT04121754

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR-001
Description: Participants will walk using the investigational device (foot sensors, mobile device with mobile app and headphones) for thirty (30) minutes at a time, 3 times a week for 5 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Walking
Description: Participants will walk for thirty (30) minutes at a time, 3 times a week for 5 weeks. No mobile devices, music players or headphones will be allowed. They will wear foot sensors during their active walking sessions to measure gait biomechanics.
Study: NCT03154177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group ANC/PNC
Description: The primary intervention is group antenatal and postnatal care wherein women receive their care in a group with other women with similar due dates. After an initial individual visit all care is given in groups although the majority of the time is dedicated to facilitated discussion and women can come for additional acute care if needed. Group antenatal care will be three group visits between 20 and 40 weeks gestation and group postnatal care will be one group visit and approximately 6 weeks post delivery.
Study: NCT01593696

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)
Description: Cells extracted, followed by induction chemotherapy before Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR) infusion (dose escalation.)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR)
Description: Cells extracted, followed by induction chemotherapy before Cluster of Differentiation (CD)19-Chimeric antigen receptor (CAR) infusion (dose escalation.)
Study: NCT01331226

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone counseling 3 sessions
Description: 3 sessions of telephone counseling
Study: NCT03154177

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group ANC/PNC
Description: The primary intervention is group antenatal and postnatal care wherein women receive their care in a group with other women with similar due dates. After an initial individual visit all care is given in groups although the majority of the time is dedicated to facilitated discussion and women can come for additional acute care if needed. Group antenatal care will be three group visits between 20 and 40 weeks gestation and group postnatal care will be one group visit and approximately 6 weeks post delivery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound+Pregnancy Testing
Description: Half of all study sites will receive early pregnancy testing, conducted by community health workers at community level and ultrasound for gestational age dating and early screening at the health center.~The primary analysis will not assess the effectiveness of this intervention.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound+Pregnancy Testing
Description: Half of all study sites will receive early pregnancy testing, conducted by community health workers at community level and ultrasound for gestational age dating and early screening at the health center.~The primary analysis will not assess the effectiveness of this intervention.
Study: NCT00976729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-E36
Description: single ascending IV doses, ranging from 0.03 mg/kg to 2.0 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-E36
Description: single ascending IV doses, ranging from 0.03 mg/kg to 2.0 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-E36
Description: single ascending IV doses, ranging from 0.03 mg/kg to 2.0 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-E36
Description: single ascending IV doses, ranging from 0.03 mg/kg to 2.0 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-E36
Description: single ascending IV doses, ranging from 0.03 mg/kg to 2.0 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-E36
Description: single ascending IV doses, ranging from 0.03 mg/kg to 2.0 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-E36
Description: single SC doses, at safe and tolerable dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX-E36
Description: single SC doses, at safe and tolerable dose level

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02087293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention arm - automated call and phone-based pharmacist counseling
Description: patients receive automated phone call with questions about side effects and an opportunity to speak with a pharmacist
Study: NCT01738685

Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional Education.
Study: NCT04396795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma
Description: Each injection session will consist of a total of 5 mL PRP infused slowly over a 2-minute period; 2.5 mL each injected to the right and left corpus cavernosum.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Each injection session will consist of a total of 5 mL saline solution infused slowly over a 2-minute period; 2.5 mL each injected to the right and left corpus cavernosum
Study: NCT03536325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 1
Description: Participants will receive Dose 1 of guselkumab on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 2
Description: Participants will receive Dose 2 of guselkumab on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 3
Description: Participants will receive Dose 3 of guselkumab on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo on Day 1.
Study: NCT02988726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Adults with a recurrent/residual Neurofibroma or Schwannoma will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT01973010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Description: Massage therapy is an intervention that can be used to relax muscle and regulate displaced joints by manual manipulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Ibuprofen is an common analgesics which has been widely used in regular control of various pain symptom.
Study: NCT02517398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSB0011359C
Description: Subjects would receive intravenous infusion of MSB0011359C once every 2 weeks in a dose escalation fashion until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
Study: NCT04426773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-Definition transcranial direct current stimulation
Description: The tDCS device will deliver a direct current of 1.5mA for 20 minutes. Cathode electrode will be localized in front of the OFC on the Fp2 point according to the EEG international reference. Four anode electrodes will be placed around FP2 (i.e. Fpz, AFz, AF4, AF8).
Study: NCT01530646

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Weight loss
Description: -750kcal/d

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: -750kcal/d

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: -750kcal/d

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy
Description: 2 x 25g/d SPC

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey
Description: 2 x 25g/d WPI
Study: NCT00553410

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -\> 36 mo) plus 1 x 12 mo in yr 5 -\> 48 months
Study: NCT05009576

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: silver alginate
Description: silver alginate hydrofiber dressing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VAC dressing without silver alginate
Description: vaccum assisted dressing